Structure-based de novo design, synthesis, and biological evaluation of non-azole inhibitors specific for lanosterol 14α-demethylase of fungi

Journal of Medicinal Chemistry

Volumn 46, Issue 4, 2003, Pages 474-485

  Ji, Haitao ^a,d   Zhang, Wannian ^a   Zhang, Min ^b   Kudo, Makiko ^c   Aoyama, Yuri ^c   Yoshida, Yuzo ^c   Sheng, Chunquan ^a   Song, Yunlong ^a   Yang, Song ^a   Zhou, Youjun ^a   Lü, Jiaguo ^a   Zhu, Jü ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

^c SOKA UNIVERSITY   (Japan)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; APOPROTEIN; CLOTRIMAZOLE; CYTOCHROME P450; ENZYME INHIBITOR; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; LANOSTEROL 14ALPHA DEMETHYLASE INHIBITOR; STEROL 14ALPHA DEMETHYLASE; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ARTICLE; CALCULATION; CANDIDA ALBICANS; DRUG BINDING SITE; DRUG DESIGN; DRUG FATALITY; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INHIBITION; FUNGUS; HUMAN; LIVER TOXICITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROTEIN FAMILY; SPECTROPHOTOMETRY; STRUCTURE ACTIVITY RELATION; TOXICITY;

ANTIFUNGAL AGENTS; BENZOPYRANS; BINDING SITES; CANDIDA ALBICANS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DESIGN; ENZYME INHIBITORS; FUNGI; HEME; MODELS, MOLECULAR; MYCOBACTERIUM TUBERCULOSIS; OXIDOREDUCTASES; PROTEIN BINDING; SPECTROPHOTOMETRY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037434588     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020362c     Document Type: Article

References (36)

1. Vanden Bossche, H.; Koymans, L. Cytochrome P450 in fungi. Mycoses 1998, 41, 32-38.
2. Yoshida, Y.; Aoyama, Y.; Noshiro, M.; Gotoh, O. Sterol 14-demethylase P450 (CYP51) provides a breakthrough for the discussion on the evolution of cytochrome P450 gene family. Biochem. Biophys. Res. Commun. 2000, 273, 799-804.
3. Kelly, S. L.; Lamb, D. C.; Cannieux, M.; Greetham, D.; Jackson, C. J.; Marczylo, T.; Ugochukwu, C.; Kelly, D. E. An old activity in the cytochrome P450 superfamily (CYP51) and a new story of drugs and resistance. Biochem. Soc. Trans. 2001, 29, 122-128.
4. Sheehan, D. J.; Hitchcock, C. A.; Sibley, C. M. Current and emerging azole antifungal agents. Clin. Microbiol. Rev. 1999, 12, 40-79.
5. Georgopapadakou, N. H.; Walsh, T. J. Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob. Agents Chemother. 1996, 40, 279-291.
6. Lupetti, A.; Danesi, R.; Campa, M.; Tacca, M. D.; Kelly, S. Molecular basis of resistance to azole antifungals. Trends Mol. Med. 2002, 8, 76-81.
7. Lamb, D. C.; Kelly, D. E.; Baldwin, B. C.; Kelly, S. L. Differential inhibition of human CYP3A4 and Candida albicans CYP51 with azole antifungal agents. Chem. Biol. Interact. 2000, 125, 165-175.
8. Slama, J. T.; Hancock, J. L.; Rho, T.; Sambucetti, L.; Bachmann, K. A. Influence of some novel N-substituted azole and pyridines on rat hepatic CYP3A activity. Biochem. Pharmacol. 1998, 55, 1881-1892.
9. + channel, IK-Ca1: a potential immunosuppressant. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 8151-8156.
10. Anaissie, E. J.; Vartivarian, S. E.; Abi-Said, D.; Uzun, O.; Pinczowski, H.; Kontoyiannis, D. P.; Khoury, P.; Papadakis, K.; Gardner, A.; Raad, I. I.; Gilbreath, J.; Bodey, G. P. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am. J. Med. 1996, 101, 170-176.
11. Bok, R. A.; Small, E. J. The treatment of advanced prostate cancer with ketoconazole: safety issues. Drug Saf. 1999, 20, 451-458.
12. Nair, D. R.; Morris, H. H. Potential fluconazole-induced carbamazepine toxicity. Ann. Pharmacother. 1999, 33, 790-792.
13. Jeng, M. R.; Feusner, J. Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia. Pediatr. Hematol. Oncol. 2001, 18, 137-142.
14. Wolf, R.; Wolf, D.; Kuperman, S. Focal nodular hyperplasia of the liver after intraconazole treatment. J. Clin. Gastroenterol. 2001, 33, 418-420.
15. Kauffman, C. A.; Hedderwick, S. A. Treatment of systemic fungal infections in older patients: achieving optimal outcomes. Drugs Aging 2001, 18, 313-323.
16. Plempel, M. Experience, recognitions and questions in azole antimycotics. Shinkin to shinkinsho 1982, 23, 17-27.
17. Fromtling R. A. Overview of medically important antifungal azole derivatives. Clin. Microbiol. Rev. 1988, 1, 187-217.
18. Ji, H.; Zhang, W.; Zhou, Y.; Zhang, M.; Zhu, J.; Song, Y.; Lü, J.; Zhu J. A three-dimensional model of lanosterol 14α-demethylase of Candida albicans and its interaction with azole antifungals. J. Med. Chem. 2000, 43, 2493-2505.
19. Podust, L. M.; Poulos, T. L.; Waterman, M. R. Crystal structure of cytochrome P450 14α-sterol demethylase (CYP51) from mycobacterium tuberculosis in complex with azole inhibitors. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 3068-3073.
20. InsightII 2000: Molecular Simulation Inc., 9685 Scranton Road, San Diego, CA 92121-3752.
21. SYBYL 6.2: Tripos Associates, Inc., 1699S. Hanley Road, Suite 303, St. Louis, MO 63144.
22. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Zakrzewski, V. G.; Montgomery, J. A., Jr.; Stratmann, R. E.; Burant, J. C.; Dapprich, S.; Millam, J. M.; Daniels, A. D.; Kudin, K. N.; Strain, M. C.; Farkas, O.; Tomasi, J.; Barone, V.; Cossi, M.; Cammi, R.; Mennucci, B.; Pomelli, C.; Adamo, C.; Clifford, S.; Ochterski, J.; Petersson, G. A.; Ayala, P. Y.; Cui, Q.; Morokuma, K.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Cioslowski, J.; Ortiz, J. V.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Gomperts, R.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Gonzalez, C.; Challacombe, M.; Gill, P. M. W.; Johnson, B. G.; Chen, W.; Wong, M. W.; Andres, J. L.; Head-Gordon, M.; Replogle, E. S.; Pople, J. A. Gaussian 98, revision A.7; Gaussian, Inc.: Pittsburgh, PA, 1998.
23. Caflisch, A.; Miranker, A.; Karplus, M. Multiple copy simultaneous search and construction of ligands in binding sites: application to inhibitors of HIV-1 aspartic proteinase. J. Med. Chem. 1993, 36, 2142-2167.
24. Evensen, E. R.; Joseph-McCarthy, D.; Karplus, M. MCSS, version 2.1; Harvard University, Cambridge, MA, 1997.
25. Böhm, H.-J. The computer program LUDI: a new method for the de novo design of enzyme inhibitors. J. Comput.-Aided Mol. Des. 1992, 6, 61-78.
26. Joseph-McCarthy, D.; Tsang, S. K.; Filman, D. J.; Hogle, J. M.; Karplus, M. Use of MCSS to design small targeted libraries: application to picornavirus ligands. J. Am. Chem. Soc. 2001, 123, 12758-12769.
27. Luty, B. A.; Wasserman, Z. R.; Stouten, P. F. W.; Hodge, C. N.; Zacharias, M.; McCammon, J. A. A molecular mechanics/grid method for evaluation of ligand-receptor interactions. J. Comput. Chem. 1995, 16, 454-464.
28. Böhm, H.-J. The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure. J. Comput.Aided Mol. Des. 1994, 8, 243-256.
29. Böhm, H.-J. Prediction of binding constants of protein ligands: A fast method for the prioritization of hits obtained from de novo design or 3D database search programs. J. Comput.-Aided Mol. Des. 1998, 12, 309-323.
30. Aoyama, Y.; Kudo, M.; Asai, K.; Okonogi, K.; Horiuchi, T.; Gotoh, O.; Yoshida, Y. Emergence of fluconazole-resistant sterol 14-demethylase P450 (CYP51) in Candida albicans is a model demonstrating the diversification mechanism of P450. Arch. Biochem. Biophys. 2000, 379, 170-171.
31. Aoyama, Y.; Yoshida, Y.; Sato, R. Yeast cytochrome P-450 catalyzing lanosterol 14α-demethylation. J. Biol. Chem. 1984, 259, 1661-1666.
32. Nitahara, Y.; Kishimoto, K.; Yabusaki, Y.; Gotoh, O.; Yoshida, Y.; Horiuchi, T.; Aoyama, Y. The amino acid residues affecting the activity and azole susceptibility of rat cyp51 (sterol 14-demethylase P450). J. Biochem. 2001, 129, 761-768.
33. Hasemann, C. A.; Kurumbail, R. G.; Boddupalli, S. S.; Peterson, J. A.; Deisenhofer, J. Structure and function of cytochromes P450: a comparative analysis of three crystal structures. Structure 1995, 2, 41-62.
34. Schlichting, I.; Berendzen, J.; Chu, K.; Stock, A. M.; Maves, S. A.; Benson, D. E.; Sweet, R. M.; Ringe, D.; Petsko, G. A.; Sligar, S. G. The Catalytic Pathway of Cytochrome P450cam at Atomic Resolution. Science 2000, 287, 1615-1622.
35. Lewis, D. F. V.; Wiseman, A.; Tarbit, M. H. Molecular modelling of lanosterol 14α-demethylase (CYP51) from Saccharomyces cerevisiae via homology with CYP102, a unique bacterial cytochrome P450 isoform: quantitative structure-activity relationships (QSARs) within two related series of antifungal azole derivatives. J. Enzyme Inhib. 1999, 14, 175-192.
36. Yoshida, Y.; Imai, Y.; Hashimoto-Yutsudo, C. Spectrophotometric examination of exogenous-ligand complexes of ferric cytochrome P-450. Characterization of the axial ligand trans to thiolate in the native ferric low-spin form. J. Biochem. 1982, 91, 1651-1659.